The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Author(s) -
Yueh–Ming Loo,
Patrick M. McTamney,
Rosalinda H. Arends,
Michael E. Abram,
Anastasia A. Aksyuk,
Seme Diallo,
Daniel J. Flores,
Elizabeth J. Kelly,
Kuishu Ren,
Richard Roque,
Kim Rosenthal,
Katie Streicher,
Kevin M. Tuffy,
Nicholas J. Bond,
Owen Cornwell,
Jérôme Bouquet,
Lily Cheng,
James Dunyak,
Yue Huang,
Anton I. Rosenbaum,
Venkatesh Pilla Reddy,
Hanné Andersen,
Robert H. Carnahan,
James E. Crowe,
Ana I. Kuehne,
Andrew S Herbert,
John M. Dye,
Helen Bright,
Nicole L. Kallewaard,
Menelas N. Pangalos,
Mark T. Esser
Publication year - 2022
Publication title -
science translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.abl8124
Subject(s) - monoclonal antibody , virology , medicine , antibody , immunology , coronavirus , epitope , neutralizing antibody , coronaviridae , virus , titer , monoclonal , biology , disease , covid-19 , infectious disease (medical specialty)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom